更正：TIM-3：一种超越检查点抑制的肿瘤相关抗原？

IF 4.1 Q2 IMMUNOLOGY Immunotherapy advances Pub Date : 2023-10-12 eCollection Date: 2023-01-01 DOI:10.1093/immadv/ltad018
{"title":"更正：TIM-3：一种超越检查点抑制的肿瘤相关抗原？","authors":"","doi":"10.1093/immadv/ltad018","DOIUrl":null,"url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1093/immadv/ltac021.].</p>","PeriodicalId":73353,"journal":{"name":"Immunotherapy advances","volume":"3 1","pages":"ltad018"},"PeriodicalIF":4.1000,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/ce/ltad018.PMC10569373.pdf","citationCount":"0","resultStr":"{\"title\":\"Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?\",\"authors\":\"\",\"doi\":\"10.1093/immadv/ltad018\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>[This corrects the article DOI: 10.1093/immadv/ltac021.].</p>\",\"PeriodicalId\":73353,\"journal\":{\"name\":\"Immunotherapy advances\",\"volume\":\"3 1\",\"pages\":\"ltad018\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2023-10-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/58/ce/ltad018.PMC10569373.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immunotherapy advances\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/immadv/ltad018\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunotherapy advances","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/immadv/ltad018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

[这更正了文章DOI:10.1093/imadv/ltac021.]。
本文章由计算机程序翻译，如有差异，请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Correction to: TIM-3: a tumor-associated antigen beyond checkpoint inhibition?

[This corrects the article DOI: 10.1093/immadv/ltac021.].

求助全文
通过发布文献求助，成功后即可免费获取论文全文。 去求助
来源期刊
Immunotherapy advances
Immunotherapy advances
CiteScore
5.00
自引率
0.00%
发文量
0
审稿时长
7 weeks
期刊最新文献
A rapid method to assess the in vivo multi-functionality of adoptively transferred engineered TCR T cells. Advancements in nuclear imaging using radiolabeled nanobody tracers to support cancer immunotherapy. Regulation of temporal cytokine production by co-stimulation receptors in TCR-T cells is lost in CAR-T cells. Cancer Vaccines: From an immunology perspective Ex Vivo Comparative Immunogenicity Assessment (EVCIA) to Determine Relative Immunogenicity in Chronic Plaque Psoriasis in Participants Receiving Humira® or Undergoing Repeated Switches Between Humira® and AVT02
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1